Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708054 | 0.87 | ALDH1A1 (0.48) | ALDH1A1POLBRAB9ATSHRPLA2G2A | |
| SCHEMBL1708039 | 0.86 | TSHR (0.45) | ALDH1A1POLBRAB9ATSHRTP53 | |
| SCHEMBL1708045 | 0.85 | ALDH1A1 (0.51) | ALDH1A1POLBRAB9ATSHRPLA2G2A | |
| SCHEMBL1707991 | 0.81 | PDE10A (0.40) | TSHRPDE10ADHODHCYP11B2ADORA2B | |
| SCHEMBL1708052 | 0.74 | ALDH1A1 (0.48) | ALDH1A1POLBRAB9ATSHRPLA2G2A | |
| SCHEMBL1708108 | 0.74 | POLB (0.53) | ALDH1A1POLBRAB9ATSHRTP53 | |
| SCHEMBL1708100 | 0.72 | RAB9A (0.51) | ALDH1A1POLBRAB9ATSHRPLA2G2A | |
| SCHEMBL1708022 | 0.72 | ALDH1A1 (0.48) | ALDH1A1POLBRAB9ATSHRPDE10A | |
| SCHEMBL1707968 | 0.72 | TSHR (0.47) | ALDH1A1POLBRAB9ATSHRTP53 | |
| SCHEMBL1707966 | 0.69 | ALDH1A1 (0.44) | ALDH1A1POLBRAB9ATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | ALDH1A1 3930/4885POLB 4829/4885RAB9A 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.